

List of compounds under investigation, open now


panna

- Dolutegravir, Tivicay/Triumeq, DTG
- Elvitegravir, Vitekta, Stribild, EVG
- Cobicistat, Tybost, Stribild, COBI
- Darunavir/cobi, RezoSta
- TAF
- Fosamprenavir, Telzir, FPV
- Tipranavir, Aptivus, TPV
- Indinavir, Crixivan, IDV
- Enfuvirtide, Fuzeon, T-20


Closed arms:

Tenofovir, emtricitabine, atazanavir, darunavir, raltegravir, abacavir, maraviroc, etravirine, efavirenz. Newly closed arm: rilpivirine.

Inclusions



Green: open arms orange: closed



Amendments:

Amendment 5, mainly adding RezoSta and TAF to the list of medications to be investigated, is being submitted in the different countries now.

Amendment 6, regarding the raltegravir once daily formulation substudy, is in the process of being developed. We will send it to you for review in January.

Funding:

Janssen will fund for RezoSta, Gilead for TAF and Merck for once daily raltegravir.

PUBLICATIONS AND PRESENTATIONS

The abacavir paper has been published in AIDS, the etravirine paper (with IMPAACT) has been published in Front Pharmacol. We published two case reports on dolutegravir in AIDS: one on the first PANNA patient and another one with Robin Kobbe from Hamburg on dolutegravir transfer in breast milk.

We presented a poster at the 17th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy: population pharmacokinetic model of efavirenz in pregnancy. Angela gave an oral presentation on the optimal timing after delivery of the postpartum curve. The population PK abstract was also awarded the Lewis B. Sheiner award at PAGE, where Stein presented this analysis.

At CROI2017 we will present a poster on rilpivirine PK in pregnancy.

Manuscripts in pipeline:

Non-compartmental analysis efavirenz in pregnancy; population pharmacokinetic model of efavirenz in pregnancy; short report on the timing of the postpartum control curve; foetal exposure PBPK model for darunavir, rilpivirine in pregnancy.

Happy New Year



Angela, Stein and David

Angela Colbers
Project manager
E-mail: Angela.Colbers@radboudumc.nl

Stein Schalkwijk
E-mail:
Stein.J.Schalkwijk@radboudumc.nl

Radboud university medical center,
Internal postal code 864, Department of
Pharmacy,
P.O. Box 9101, 6500 HB Nijmegen
Phone: + 31 (0)24 - 361 64 05